New Delhi: Former AIIMS director M C Misra has been awarded the honorary fellowship of the prestigious Royal College of Surgeons of Edinburgh, a first for an Indian doctor in the last five years.
Set up in 1505, the Royal College is one of the worlds oldest and largest surgical establishments.
"It is with great pleasure, we write on behalf of Royal College of Surgeons of Edinburgh to invite you to accept the award of fellowship ad hominem (Honorary fellowship)," stated a letter to Misra by the organisation.
The institute has an international network with a membership of around 20,000 in almost 100 countries.
Misra, a renowned surgeon, retired on January 31 this year after serving as the director of AIIMS for over three years.
Misra also served as the chief of AIIMS Trauma from June 2008.
In his 39-month tenure, Mishra contributed to the Apex Medical Sciences University of India. He also led AIIMS delegations to the EAS Round Table Conference on Trauma Care, the World Trauma Congress and the 2 AIIMS-FAM conferences in New Delhi and Paris.
He is credited with the creation of the new departments of Rheumatology and Burns and Plastic Surgery. He also played a significant role in the Digital AIIMS project.
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!